avibactam sodium and its Impurities
This combination was approved by the FDA on Avibactam is a non-β-lactam β-lactamase inhibitor that is available in combination with ceftazidime (Avycaz). This combination was approved by the FDA on February 25, 2015 for the treatment of complicated intra-abdominal infections in combination . Reference standards of Avibactam Sodium API, and its pharmacopeial, non pharmacopeial impurities, and stable isotopes are listed below.